EUVIMEDEUVIMED entdecken
Open Access

Development of a fibrin-targeted theranostic for gastric cancer

Shadi A Esfahani iD, Li Ma, Shriya Krishna, Hua Ma iD, Shvan J Raheem iD, Sergey Shuvaev, Nicholas J Rotile iD, Jonah Weigand-Whittier, Avery T Boice, Nicholas Borges iD, Constantina A Treaba, Caitlin Deffler iD und 10 weitere

Science Translational Medicine · 11.12.2024 · 16 (777)

DOI: 10.1126/scitranslmed.adn7218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 11.12.2024. Verfasst von Shadi A Esfahani und 21 weiteren Autor:innen. Beteiligte Einrichtung: Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Fibrin, Positron-Emission Tomography. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with advanced gastric cancer (GCa) have limited treatment options, and alternative treatment approaches are necessary to improve their clinical outcomes. Because fibrin is abundant in gastric tumors but not in healthy tissues, we hypothesized that fibrin could be used as a high-concentration depot for a high-energy beta-emitting cytotoxic radiopharmaceutical delivered to tumor cells. We showed that fibrin is present in 64 to 75% of primary gastric tumors and 50 to 100% of metastatic gastric adenocarcinoma cores. First-in-human 64 Cu-FBP8 fibrin–targeted positron emission tomography (PET) imaging in seven patients with gastric or gastroesophageal junction cancer showed high probe uptake in all target lesions with tumor-to-background (muscle) uptake ratios of 9.9 ± 6.6 in primary ( n = 7) and 11.2 ± 6.6 in metastatic ( n = 45) tumors. Using two mouse models of human GCa, one fibrin-high (SNU-16) and one fibrin-low (NCI-N87), we showed that PET imaging with a related fibrin-specific peptide, CM500, labeled with copper-64 ( 64 Cu-CM500) specifically bound to and precisely quantified tumor fibrin in both models. We then labeled the fibrin-specific peptide CM600 with yttrium-90 and showed that 90 Y-CM600 effectively decreased tumor growth in these mouse models. Mice carrying fibrin-high SNU-16 tumors experienced tumor growth inhibition and prolonged survival in response to either a single high dosage or fractionated lower dosage of 90 Y-CM600, whereas mice carrying fibrin-low NCI-N87 tumors experienced prolonged survival in response to a fractionated lower dosage of 90 Y-CM600. These results lay the foundation for a fibrin-targeted theranostic that may expand options for patients with advanced GCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsFibrinPositron-Emission TomographyHumansAnimalsCell Line, TumorMiceCopper RadioisotopesTheranostic NanomedicineFemalePrecision Medicine

Substanzen

FibrinCopper Radioisotopes

Autor:innen und Institutionen

  • Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Collagen Medical LLC, Boston, MA 02116, USA.
  • Cardiovascular Research Center, Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
  • Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Division of Hematology-Oncology, Mass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

ORCID-Profile: Shadi A Esfahani, Hua Ma, Shvan J Raheem, Nicholas J Rotile, Nicholas Borges, Caitlin Deffler, Himashinie Diyabalanage, Valerie Humblet, David E Sosnovik, Umar Mahmood, Pedram Heidari, Angela Shih, Matthew R Strickland, Samuel J Klempner, Peter Caravan

Förderung

  • NIH HHS
  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Esfahani, S. A., Ma, L., Krishna, S., Ma, H., Raheem, S. J., Shuvaev, S., Rotile, N. J., Weigand-Whittier, J., Boice, A. T., Borges, N., Treaba, C. A., Deffler, C., Diyabalanage, H., Humblet, V., Sosnovik, D. E., Mahmood, U., Heidari, P., Shih, A., Catana, C., …, & Caravan, P. (2024). Development of a fibrin-targeted theranostic for gastric cancer. Science Translational Medicine, 16(777). https://doi.org/10.1126/scitranslmed.adn7218

Vancouver

Esfahani SA, Ma L, Krishna S, Ma H, Raheem SJ, Shuvaev S, et al. Development of a fibrin-targeted theranostic for gastric cancer. Science Translational Medicine. 2024;16(777). doi:10.1126/scitranslmed.adn7218

BibTeX
@article{Esfahani2024,
  author = {Esfahani, Shadi A and Ma, Li and Krishna, Shriya and Ma, Hua and Raheem, Shvan J and Shuvaev, Sergey and Rotile, Nicholas J and Weigand-Whittier, Jonah and Boice, Avery T and Borges, Nicholas and Treaba, Constantina A and Deffler, Caitlin and Diyabalanage, Himashinie and Humblet, Valerie and Sosnovik, David E and Mahmood, Umar and Heidari, Pedram and Shih, Angela and Catana, Ciprian and Strickland, Matthew R and Klempner, Samuel J and Caravan, Peter},
  title = {Development of a fibrin-targeted theranostic for gastric cancer},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {777},
  doi = {10.1126/scitranslmed.adn7218}
}
Kostenlos starten →